Spero Therapeutics, Inc. (SPRO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Spero Therapeutics, Inc. (SPRO) Healthcare & Pipeline Overview

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in treatments for multi-drug resistant bacterial infections and rare diseases. Their focus on oral and IV antibiotics, including tebipenem HBr and SPR206, positions them to address unmet needs in the infectious disease market, supported by strategic partnerships.

What Is the Investment Thesis for SPRO?

Spero Therapeutics presents a focused investment opportunity within the biotechnology sector, targeting the critical area of multi-drug resistant bacterial infections. The company's lead candidate, tebipenem HBr, addresses a significant unmet need in the treatment of complicated urinary tract infections, with potential for market adoption given its oral formulation. Key value drivers include successful clinical trial outcomes, regulatory approvals, and commercialization partnerships. The company's gross margin of 77.5% indicates strong potential profitability upon successful product launches. Growth catalysts include ongoing clinical trials for SPR206 and SPR720, which could expand the company's pipeline and market reach. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. Spero's market capitalization of $64.8M, coupled with a P/E ratio of 8.00, suggests a potentially undervalued company if its pipeline candidates achieve commercial success.

Based on FMP financials and quantitative analysis

SPRO Key Highlights

Market Cap of $64.8M reflects the company's current valuation in the biopharmaceutical market.

• P/E Ratio of 8.00 indicates the price investors are willing to pay for each dollar of Spero's earnings.
• Profit Margin of 14.2% demonstrates the company's ability to generate profit from its revenue streams.
• Gross Margin of 77.5% highlights the efficiency of Spero's operations and the value of its products.
• Beta of 1.45 suggests that Spero's stock is more volatile than the overall market.

Who Are SPRO's Competitors?

SPRO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are SPRO's Key Strengths?

Innovative pipeline of antibiotic therapies.

• Strategic partnerships with established pharmaceutical companies.
• Focus on addressing unmet medical needs in infectious disease.
• Experienced management team with expertise in drug development.

What Are SPRO's Weaknesses?

Reliance on successful clinical trial outcomes.

• Dependence on regulatory approvals.
• Competition from established pharmaceutical companies.
• Limited financial resources compared to larger competitors.

What Could Drive SPRO Stock Higher?

Clinical trial results for SPR206 in treating MDR Gram-negative bacterial infections (2027).

• Regulatory submission for tebipenem HBr for the treatment of complicated urinary tract infections (2026).
• Expansion of strategic partnerships to broaden pipeline and market reach.
• Advancements in the development of SPR720 for non-tuberculous mycobacterial pulmonary disease.

What Are the Key Risks for SPRO?

Financial-distress signal — its Altman Z-Score of -5.47 sits in the distress zone (elevated bankruptcy risk).

• Clinical trial failures for key product candidates.
• Regulatory delays or rejections for new drug applications.
• Competition from established pharmaceutical companies with greater resources.
• Changes in healthcare regulations and reimbursement policies.
• Intellectual property challenges and patent disputes.

What Are the Growth Opportunities for SPRO?

• Expansion of Tebipenem HBr: Spero has the opportunity to expand the market for tebipenem HBr beyond complicated urinary tract infections to other indications. This could involve conducting clinical trials to evaluate its efficacy against other types of bacterial infections. The global market for UTI treatment is projected to reach $9.7 billion by 2027, providing a substantial opportunity for Spero to increase its revenue. Timeline: 2026-2028.
• Development of SPR206: SPR206, an IV-administered agent, targets MDR Gram-negative bacterial infections in hospitals. Successful development and commercialization could address a critical unmet need in hospital settings. The market for hospital-acquired infection treatments is expected to grow, driven by increasing rates of antibiotic resistance. Spero's collaboration with Everest Medicines provides access to the Greater China, South Korea, and Southeast Asian markets. Timeline: 2027-2029.
• Advancement of SPR720: SPR720 is an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. This represents a significant growth opportunity, as NTM infections are becoming increasingly prevalent. Spero's collaboration with the Bill & Melinda Gates Medical Research Institute supports the development of SPR720. The market for NTM treatments is expected to grow, driven by increasing awareness and diagnosis of the disease. Timeline: 2028-2030.
• Strategic Partnerships: Spero can pursue additional strategic partnerships to expand its pipeline and market reach. Collaborations with pharmaceutical companies, research institutions, and government agencies can provide access to funding, expertise, and new technologies. These partnerships can accelerate the development and commercialization of Spero's product candidates. The biotechnology industry is characterized by frequent collaborations and partnerships, providing numerous opportunities for Spero. Timeline: Ongoing.
• Geographic Expansion: Spero can expand its geographic presence beyond the United States through strategic partnerships and direct commercialization efforts. The global market for antibiotics is growing, particularly in emerging markets. Spero's collaboration with Everest Medicines provides access to key Asian markets. Expanding into Europe and other regions can further increase the company's revenue and market share. Timeline: 2028-2032.

What Are SPRO's Competitive Advantages?

• Proprietary drug formulations and intellectual property protection.
• Strategic partnerships with established pharmaceutical companies.
• Focus on addressing unmet medical needs in infectious disease.
• Expertise in developing and commercializing antibiotic therapies.

What Does SPRO Do?

Founded in 2013 and headquartered in Cambridge, Massachusetts, Spero Therapeutics, Inc. is dedicated to identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. The company's mission is to provide innovative solutions to combat the growing threat of antibiotic resistance, addressing critical unmet needs in the healthcare sector. Spero's lead product candidate, tebipenem pivoxil hydrobromide (HBr), is an oral carbapenem-class antibiotic designed to treat complicated urinary tract infections (cUTI), including pyelonephritis, in adults. This oral formulation offers a convenient alternative to intravenous administration, potentially reducing hospital stays and improving patient outcomes. Another key asset in Spero's pipeline is SPR206, a direct-acting, IV-administered agent targeting MDR Gram-negative bacterial infections in hospital settings. SPR206 aims to address severe infections where existing antibiotics are ineffective. Additionally, Spero is developing SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial (NTM) pulmonary disease, a chronic and debilitating condition. Spero has established strategic collaborations to support the development and commercialization of its product candidates. These include a license agreement with Meiji Seika Pharma Co., Ltd. for tebipenem HBr, a license agreement with Everest Medicines for SPR206 in Greater China, South Korea, and Southeast Asian countries, a collaboration agreement with Bill & Melinda Gates Medical Research Institute for SPR720, and a license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720 and SPR719.

What Products and Services Does SPRO Offer?

• Develops oral antibiotics to treat complicated urinary tract infections.
• Creates IV-administered agents to combat multi-drug resistant Gram-negative bacterial infections.
• Focuses on treatments for non-tuberculous mycobacterial pulmonary disease.
• Identifies and develops therapies for rare diseases.
• Commercializes treatments for multi-drug resistant bacterial infections.
• Collaborates with pharmaceutical companies and research institutions to advance drug development.
• Seeks to address unmet medical needs in infectious disease.

How Does SPRO Make Money?

• Develops and licenses pharmaceutical products.
• Generates revenue through licensing agreements with other companies.
• Conducts clinical trials to demonstrate the efficacy and safety of its product candidates.
• Seeks regulatory approvals from the FDA and other regulatory agencies.
• Commercializes its products through its own sales force or through partnerships.

What Industry Does SPRO Operate In?

Spero Therapeutics operates in the biotechnology industry, which is characterized by high innovation, intense competition, and significant regulatory oversight. The increasing prevalence of multi-drug resistant bacterial infections is driving demand for new and effective antibiotics. The market for antibiotic therapies is projected to grow, driven by factors such as an aging population, increased international travel, and the overuse of antibiotics. Spero's focus on oral antibiotics, such as tebipenem HBr, positions it to compete with established pharmaceutical companies offering intravenous therapies. The company's strategic partnerships, including those with Meiji Seika Pharma and Everest Medicines, enhance its market reach and development capabilities.

Who Are SPRO's Key Customers?

• Hospitals and healthcare providers treating patients with multi-drug resistant bacterial infections.
• Patients suffering from complicated urinary tract infections.
• Patients with non-tuberculous mycobacterial pulmonary disease.
• Pharmaceutical companies that license Spero's products.

Company Profile

Spero Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, United States.

Spero Therapeutics, Inc. Financial Trajectory

Spero Therapeutics, Inc. (SPRO) reported $0 in revenue for Q2 FY2026, a decline of 100.0% compared to the prior quarter. The company recorded a net loss of $9.6M, with diluted EPS of $-0.16. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, SPRO averaged $0.03 in diluted EPS.

How Spero Therapeutics, Inc. Is Valued

Spero Therapeutics, Inc. carries a market capitalization of $64.8M, placing it in the micro-cap category. Relative to its peer group, SPRO's quantitative score of 40/100 is below the peer average of 77/100.

Return on equity for Spero Therapeutics, Inc. stands at 16.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 14.0%, showing how much profit it generates from its asset base. SPRO trades at a trailing price-to-earnings ratio of 8.00, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 27.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.12 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 10.4%, the inverse of the P/E and a quick read on earnings relative to price.

Spero Therapeutics, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -5.47 places it in the distress zone, a signal of elevated financial risk.

Spero Therapeutics, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 70.8% above estimates on average.

Over the past six months, Spero Therapeutics, Inc. insiders filed 17 SEC Form 4 transactions — 1 sales and 16 purchases. On net that is roughly 672K shares acquired (about $738K) — insiders putting money in tends to read as conviction.

SPRO Financials

SPRO Latest News

SPRO Analyst Consensus

SPRO MoonshotScore

Common Questions About SPRO (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources